Ongoing concerns about Avandia (rosiglitazone)

Ongoing concerns about Avandia (rosiglitazone) will prompt more safety review by FDA. Its end is in sight.
You'll hear more in July when FDA advisors will consider whether to recommend withdrawing Avandia from the market.
A recent Senate report claims many people needlessly suffer heart attacks by using Avandia instead of Actos (pioglitazone).
There's really NO benefit to using Avandia over Actos.
Plan on seeing Avandia go off the market or used less.
If FDA doesn't take it off the market now, it will become essentially obsolete when Actos goes early as next year.
Refer questions about Avandia to the pharmacist.
Stay alert for inappropriate dosing when a switch is made.

Actos 15 mg/day is usually used for patients on Avandia 4 mg/day...

and Actos 30 mg/day for Avandia 8 mg/day.
Get our Avandia Patient Handout before the next uproar to help your pharmacist answer questions.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote